Published online before print July 28, 2005, doi: 10.1161/01.STR.0000177517.01203.eb
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2005;36:1954.)
© 2005 American Heart Association, Inc.
Original Contributions |
Tissue Plasminogen Activator Promotes Matrix Metalloproteinase-9 Upregulation After Focal Cerebral Ischemia
From the Neuroprotection Research Laboratory (K.T., T.A., E.T., K.A., S.-R.L., X.W., E.H.L.), Departments of Neurology and Radiology, Massachusetts General Hospital, and Program in Neuroscience, Harvard Medical School, Charlestown, Mass; Department of Neurosurgery (K.T.), Kinki University School of Medicine, Osaka-sayama, Japan; Cardiovascular Research Center and Department of Medicine (D.N.A., P.L.H.), Massachusetts General Hospital and Harvard Medical School, Charlestown, Mass; Department of Life Science (S.-R.L.), Cheju National University, Korea; and Neurovascular Research Laboratory and the Stroke Unit (J.M.), Hospital Universitario Vall d’Hebron, Barcelona, Spain.
Correspondence to Eng H. Lo, Neuroprotection Research Laboratory, Harvard Medical School, MGH E 149-2401, Charlestown, MA 02129. E-mail lo{at}helix.mgh.harvard.edu
Background and Purpose— Thrombolytic therapy with tissue plasminogen activator (tPA) in ischemic stroke is limited by increased risks of cerebral hemorrhage and brain injury. In part, these phenomena may be related to neurovascular proteolysis mediated by matrix metalloproteinases (MMPs). Here, we used a combination of pharmacological and genetic approaches to show that tPA promotes MMP-9 levels in stroke in vivo.
Methods— In the first experiment, spontaneously hypertensive rats were subjected to 3 hours of transient focal cerebral ischemia. The effects of tPA (10 mg/kg IV) on ischemic brain MMP-9 levels were assessed by zymography. In the second experiment, wild-type (WT) and tPA knockout mice were subjected to 2 hours of transient focal cerebral ischemia, and MMP-9 levels and brain edema during reperfusion were assessed. Phenotype rescue was performed by administering tPA to the tPA knockout mice.
Results— In the first experiment, exogenous tPA did not change infarct size but amplified MMP-9 levels in ischemic rat brain at 24 hours. Coinfusion of the plasmin inhibitor tranexamic acid (300 mg/kg) did not ameliorate this effect, suggesting that it was independent of plasmin. In the second experiment, ischemic MMP-9 levels, infarct size, and brain edema in tPA knockouts were significantly lower than WT mice. Administration of exogenous tPA (10 mg/kg IV) did not alter infarction but reinstated the ischemic MMP-9 response back up to WT levels and correspondingly worsened edema.
Conclusions— These data demonstrate that tPA upregulates brain MMP-9 levels in stroke in vivo, and suggest that combination therapies targeting MMPs may improve tPA therapy.
Key Words: blood–brain barrier • brain edema • metalloproteinases • mice • tissue plasminogen activator
This article has been cited by other articles:
 |
|
 |
|
  L. S. Machado, I. Y. Sazonova, A. Kozak, D. C. Wiley, A. B. El-Remessy, A. Ergul, D. C. Hess, J. L. Waller, and S. C. Fagan Minocycline and Tissue-Type Plasminogen Activator for Stroke: Assessment of Interaction Potential Stroke, September 1, 2009; 40(9): 3028 - 3033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Cuadrado, L. Ortega, M. Hernandez-Guillamon, A. Penalba, I. Fernandez-Cadenas, A. Rosell, and J. Montaner Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release J. Leukoc. Biol., July 1, 2008; 84(1): 207 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Moldes, T. Sobrino, M. Millan, M. Castellanos, N. Perez de la Ossa, R. Leira, J. Serena, J. Vivancos, A. Davalos, and J. Castillo High Serum Levels of Endothelin-1 Predict Severe Cerebral Edema in Patients With Acute Ischemic Stroke Treated With t-PA Stroke, July 1, 2008; 39(7): 2006 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, J. Liu, H. Zhu, E. Tejima, K. Tsuji, Y. Murata, D. N. Atochin, P. L. Huang, C. Zhang, and E. H. Lo Effects of Neuroglobin Overexpression on Acute Brain Injury and Long-Term Outcomes After Focal Cerebral Ischemia Stroke, June 1, 2008; 39(6): 1869 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Adhami, D. Yu, W. Yin, A. Schloemer, K. A. Burns, G. Liao, J. L. Degen, J. Chen, and C.-Y. Kuan Deleterious Effects of Plasminogen Activators in Neonatal Cerebral Hypoxia-Ischemia Am. J. Pathol., June 1, 2008; 172(6): 1704 - 1716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rosell, E. Cuadrado, A. Ortega-Aznar, M. Hernandez-Guillamon, E. H. Lo, and J. Montaner MMP-9-Positive Neutrophil Infiltration Is Associated to Blood-Brain Barrier Breakdown and Basal Lamina Type IV Collagen Degradation During Hemorrhagic Transformation After Human Ischemic Stroke Stroke, April 1, 2008; 39(4): 1121 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Saguchi, H. Onoue, M. Urashima, T. Ishibashi, T. Abe, and H. Furuhata Effective and Safe Conditions of Low-Frequency Transcranial Ultrasonic Thrombolysis for Acute Ischemic Stroke: Neurologic and Histologic Evaluation in a Rat Middle Cerebral Artery Stroke Model Stroke, March 1, 2008; 39(3): 1007 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Kelly, J. D. Morrow, M. Ning, W. Koroshetz, E. H. Lo, E. Terry, G. L. Milne, J. Hubbard, H. Lee, E. Stevenson, et al. Oxidative Stress and Matrix Metalloproteinase-9 in Acute Ischemic Stroke: The Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) Study Stroke, January 1, 2008; 39(1): 100 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Benarroch Tissue plasminogen activator: Beyond thrombolysis Neurology, August 21, 2007; 69(8): 799 - 802. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lin, K.S. Kazmi, M. Law, J. Babb, N. Peccerelli, and B.K. Pramanik Measuring Elevated Microvascular Permeability and Predicting Hemorrhagic Transformation in Acute Ischemic Stroke Using First-Pass Dynamic Perfusion CT Imaging AJNR Am. J. Neuroradiol., August 1, 2007; 28(7): 1292 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. del Zoppo, R. Milner, T. Mabuchi, S. Hung, X. Wang, G. I. Berg, and J. A. Koziol Microglial Activation and Matrix Protease Generation During Focal Cerebral Ischemia Stroke, February 1, 2007; 38(2): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-Q. Zhao, E. Tejima, and E. H. Lo Neurovascular Proteases in Brain Injury, Hemorrhage and Remodeling After Stroke Stroke, February 1, 2007; 38(2): 748 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Millan, T. Sobrino, M. Castellanos, F. Nombela, J. F. Arenillas, E. Riva, I. Cristobo, M. M. Garcia, J. Vivancos, J. Serena, et al. Increased Body Iron Stores Are Associated With Poor Outcome After Thrombolytic Treatment in Acute Stroke Stroke, January 1, 2007; 38(1): 90 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Krizanac-Bengez, M. Hossain, V. Fazio, M. Mayberg, and D. Janigro Loss of flow induces leukocyte-mediated MMP/TIMP imbalance in dynamic in vitro blood-brain barrier model: role of pro-inflammatory cytokines Am J Physiol Cell Physiol, October 1, 2006; 291(4): C740 - C749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Hess NXY-059: A Hopeful Sign in the Treatment of Stroke Stroke, October 1, 2006; 37(10): 2649 - 2650. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Fulcher, S. T. Hashimi, E. L. Levroney, M. Pang, K. B. Gurney, L. G. Baum, and B. Lee Galectin-1-Matured Human Monocyte-Derived Dendritic Cells Have Enhanced Migration through Extracellular Matrix J. Immunol., July 1, 2006; 177(1): 216 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-R. Lee, H.-Y. Kim, J. Rogowska, B.-Q. Zhao, P. Bhide, J. M. Parent, and E. H. Lo Involvement of matrix metalloproteinase in neuroblast cell migration from the subventricular zone after stroke. J. Neurosci., March 29, 2006; 26(13): 3491 - 3495. [Abstract] [Full Text] [PDF]
|
|